Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 14;74(1):24.
doi: 10.1007/s00262-024-03872-6.

Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma

Yu-Zhe Cao  1   2   3 , Jia-Yu Pan  1   2   3 , Guang-Lei Zheng  1   2   3 , Chao An  4   5   6 , Meng-Xuan Zuo  7   8   9
Affiliations

Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma

Yu-Zhe Cao et al. Cancer Immunol Immunother. .

Abstract

Background and aims: The goal of this study was to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with targeted therapy and PD-(L)1 blockade (triple therapy), either sequentially (SE) or simultaneously (SI), in the treatment of Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC).

Approach and results: From January 1, 2018, to June 1, 2022, 575 patients with BCLC stage C HCC who underwent SE or SI triple therapy were retrospectively enrolled. Propensity score matching (PSM; 1:1) was performed to eliminate possible confounder imbalances across cohorts. We used the Kaplan-Meier method and a log-rank test to compare the overall survival (OS) and progression-free survival (PFS) rates between the SI and SE groups. The tumor response and the incidence of adverse events (AEs) were reported. After PSM, 182 patients in each of the two groups were matched. The median OS in the SI group was significantly longer than that in the SE group (28.8 vs. 16.1 months; P = 0.002), and the median PFS was significantly improved in the SI versus SE group (9.6 vs. 7.0 months; P = 0.01). The objective response rate based on the mRECIST was higher in the SI group (58% vs. 37%; P < 0.001). The total incidences of grade 3-4 AEs were 111/182 (60.9%) and 128/182 (70.3%) in the SE and SI groups, respectively. No grade 5 AEs were reported in either group.

Conclusions: Simultaneous HAIC plus targeted therapy and PD-(L)1 blockade significantly improved outcomes compared to the sequential regimen in patients with BCLC stage C HCC, with no unexpected AEs.

Clinical relevance statement: The patients who received hepatic arterial infusion chemotherapy combined with targeted therapy and PD-(L)1 blockade simultaneously have a better prognosis than those who received it sequentially.

Keywords: Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; PD-(L)1 blockade; Sequentially and simultaneously; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations Conflict of interests The authors declare no competing interests. Ethical statement All patients were followed up under the hospital ethics committee approval of Sun Yat-sen University Cancer Center (B2023-362–01). The principles of the Declaration of Helsinki were followed.

Figures

Fig. 1
Fig. 1
A: flowchart of BCLC stage C HCC patients who received triple therapy; B: treatment schedules of sequential and simultaneous group groups. HAIC, hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma
Fig. 2
Fig. 2
As determined by Kaplan–Meier analyses, comparisons of progression-free survival A before or B after PSM and overall survival C before or D after PSM between the two groups. PSM, propensity score matching
Fig. 3
Fig. 3
Cox regression analyses of overall survival: (A) univariate and (B) multivariate. HAIC, hepatic arterial infusion chemotherapy; AFP, alpha-fetoprotein; MVI, macrovascular invasion; and EHM, extrahepatic metastasis
Fig. 4
Fig. 4
Subgroup analyses of overall survival for the sequential and simultaneous protocols. HAIC, hepatic arterial infusion chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; AFP, alpha-fetoprotein; MVI, macrovascular invasion; and EHM, extrahepatic metastasis
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249 - PubMed
    1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557–2576 - PubMed
    1. Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP et al (2020) Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO. MOS and SSO Ann Oncol 31(3):334–351 - PubMed
    1. Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76(3):681–693 - PMC - PubMed
    1. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10(1):35–43 - PubMed

MeSH terms

Substances